AriBio Co., Ltd., a Phase 3 biopharmaceutical company, RESTARI, a company focused on severe kidney diseases, today announced that the companies have entered into an exclusive license and ...

"Groups such as the American College of Medical Genetics and Genomics can use this study to help determine whether PKD1 and PKD2 should be considered in future recommendations for reporting of ...

Polycystic kidney disease (PKD) is a debilitating hereditary condition in which fluid-filled sacs form and proliferate in the kidneys. Over time, the painful, growing cysts rob the organs of their ...

University of Oklahoma College of Medicine researchers Maulin Patel, Ph.D., left, and Leonidas Tsiokas, Ph.D., are seeking the mechanisms of polycystic kidney disease. For many patients, dialysis – a ...

Polycystic kidney disease (PKD), a family of genetic disorders that causes clusters of cysts to form on the kidney, is among the most common genetic disorders, affecting some 500,000 people in the ...

Autosomal dominant polycystic kidney disease (PKD) is a chronic and debilitating condition affecting over 12 million patients worldwide. PKD arises from mutations in the polycystin-1 (PC1) or PC2 ...

Please provide your email address to receive an email when new articles are posted on . The study reported elevated adjusted rates for four non-pulmonary complications in those with vs. without cystic ...

A study of kidney organoids in a novel lab environment might have downstream implications for the treatment of polycystic kidney disease (PKD), an incurable condition that affects more than 12 million ...